Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

Lupin share price today

LUPINPharmaConsolidatedPrices to 18 Nov 2026Results to Sep 2026

Price, 200-day average and NIFTY 500

The price is 8.7% below its 200-day average and 64 points ahead of the NIFTY 500 over 5 years

18 Nov 2026₹1,971.90Over 5 years: Lupin +119.4%, NIFTY 500 +55.7%
₹1,000₹2,000Nov 22Nov 24Nov 26

Price growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y−2.8%3Y+18.1%/yr5Y+17.0%/yr10Y+3.4%/yr

EPS and P/E

EPS ₹113.92, up 20% in a year; P/E 17.3

18 Nov 2026₹113.92 EPS
Mar 22
Jun 22
Sep 22
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
Nov 26
₹150−₹50

EPS growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+20.2%3Y+57.3%/yr5YToo short10YToo short

Revenue and margins

Revenue up on a year for 17 quarters in a row; operating margin 26.1%

Sep 2026 quarter₹7,827 crore+11.1% on ₹7,048 crore a year earlier · NPM 14.8%
Dec 21
Mar 22
Jun 22
Sep 22
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
0₹10,000

Revenue: 1Y change, then growth a year; margins are averages

Revenue growth1Y+24.2%3Y+18.2%/yr5Y+13.0%/yr to Mar10Y+7.0%/yr to Mar
OPM average3Y26.8%5Y18.5% to Mar
NPM average3Y15.9%5Y9.2% to Mar

Return on capital

ROCE was 26.7% for the four quarters to Sep 2026, up from -7.0% in the year to Mar 2022

Four quarters to Sep 202626.7% ROCE
0%30%Sep 22Sep 24Sep 26

ROCE average

1Y3Y5Y10Y1Y26.7%3Y22.5% to Mar5Y13.3% to Mar10Y12.4% to Mar

Profit and cash

Cash from operations was 171% of profit over five years, 137% in the year to Mar 2026

Yearly profit, cash from operations and free cash flow, ₹ crore

FY26₹7,334 crore operating cashProfit ₹5,355 crore · Free cash ₹5,280 crore
FY22
FY23
FY24
FY25
FY26
0₹10,000

Profit growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+20.1%3Y+57.1%/yr5Y+34.2%/yr to Mar10Y+9.0%/yr to Mar

Reinvestment

Capex was ₹2,055 crore in the year to Mar 2026, 1.5 times depreciation

FY26₹2,055 crore capexWork in progress ₹1,016 crore
FY22
FY23
FY24
FY25
FY26
0₹2,500

Capex growth: 1Y change, then growth a year

1Y3Y5Y10Y1Y+22.1% to Mar3Y+11.1%/yr to Mar5YToo short10YToo short

BorrowingsInsufficient history, from Sep 2022Insufficient history, from Sep 2022

Debt ÷ equity 0.26 at 30 Sep 2026; profit covered interest 16.6x over the last four quarters

Sep 2026 balance sheet0.26 debt ÷ equityNet cash ₹1,363 crore
Sep 22
Dec 22
Mar 23
Jun 23
Sep 23
Dec 23
Mar 24
Jun 24
Sep 24
Dec 24
Mar 25
Jun 25
Sep 25
Dec 25
Mar 26
Jun 26
Sep 26
030x

Safety

Now3Y ago
Debt ÷ equity0.263Y ago0.28
Int. cover16.6x3Y ago5.9x

Operating health

Working capital fell from 34 to 28 days in 5 years

Year to Mar 202628 days working capital
100300Mar 22Mar 24Mar 26
Working cap.281Y−303Y−45Y−6
Debtor861Y−23Y−125Y−22
Inventory3031Y+113Y+615Y+24

OwnershipInsufficient history, from Mar 2023Insufficient history, from Mar 2023

FIIs own 23.28%, up 2.78 points in a year. Promoters hold 46.84%

Share of the company held, %, by quarter end

Sep 2026 quarter23.28% FIIs
20%40%Sep 23Sep 24Sep 25Sep 26

Change in holding, in points

FIIs1Y+2.783Y+8.29
Promoters1Y−0.053Y−0.22

Lupin Ltd · LUPIN · Pharma - Formulators · price as of the 18 November 2026 close, updated every trading day · results updated weekly · research updated 4 November 2026

Lupin share price today: ₹1,971.90 at the close on 18 November 2026, down 2.8% in a year. Lupin (LUPIN) is worth ₹90,188 crore, trades at a P/E of 17.3 and has closed between ₹1,928.90 and ₹2,496.30 over the past 52 weeks. Latest change: profit fell in the September 2026 quarter.

MixedBusiness trend from the last 12 quarters
₹1,971.90Price −2.8% in a year
17.3×P/E lower than 96% of the last 11 years
₹7,827 CrRevenue (Sep 2026) +11.1% on a year ago
₹1,155 CrProfit (Sep 2026) −22.2% on a year ago
26.1%Operating margin −7.1 points on a year ago
26.7%ROCE four quarters to Sep 2026
24.3%ROIC against a 12.0% cost of capital: +12.3 points

Lupin Ltd's P/E is near the low end of its own history, higher than only 4% of past readings, and its quarterly results are still getting worse.

The main question: the P/E is near the low end of its own history, higher than only 4% of past readings, but results are getting worse. A low multiple can stay low until the quarters turn.

The price has been falling for 7 weeks, and the P/E is lower than 96% of its own last 11 years. Over the last four quarters, results have been deteriorating, with profit −22.2% on a year earlier, and 132% of the last 3 years' profit came in as cash. What will decide it: whether results start to improve.

What is the Lupin share price today?

Lupin Ltd's share price was ₹1,971.90 at the close on 18 November 2026. It has been falling for 7 weeks. That is 8.7% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,929 and ₹2,496, and at that close it sat 8% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Lupin Ltd is in stage 4. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 17 weeks running.

Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?

Ahead in 220 of 555 weeks

Week by week since 2016: did it beat the NIFTY 500 over the past 13 weeks?
Week13-week return vs NIFTY 500
26 Feb 2016no NIFTY 500 reading
4 Mar 2016no NIFTY 500 reading
11 Mar 2016no NIFTY 500 reading
18 Mar 2016no NIFTY 500 reading
23 Mar 2016no NIFTY 500 reading
1 Apr 2016no NIFTY 500 reading
8 Apr 2016no NIFTY 500 reading
13 Apr 2016no NIFTY 500 reading
22 Apr 2016no NIFTY 500 reading
29 Apr 2016no NIFTY 500 reading
6 May 2016no NIFTY 500 reading
13 May 2016no NIFTY 500 reading
20 May 2016no NIFTY 500 reading
27 May 2016−30.4%
3 Jun 2016−28.2%
10 Jun 2016−31.7%
17 Jun 2016−14.0%
24 Jun 2016−9.5%
1 Jul 2016−3.0%
8 Jul 2016−4.5%
15 Jul 2016−1.6%
22 Jul 2016+0.1%
29 Jul 2016−3.0%
5 Aug 2016−7.7%
12 Aug 2016−12.0%
19 Aug 2016−8.8%
26 Aug 2016−5.8%
2 Sep 2016−5.0%
9 Sep 2016−1.7%
16 Sep 2016−4.4%
23 Sep 2016−9.7%
30 Sep 2016−9.5%
7 Oct 2016−15.4%
14 Oct 2016−15.7%
21 Oct 2016−16.2%
30 Oct 2016−15.0%
4 Nov 2016−13.9%
11 Nov 2016−4.8%
18 Nov 2016−3.4%
25 Nov 2016+4.9%
2 Dec 2016+5.5%
9 Dec 2016+2.6%
16 Dec 2016+2.4%
23 Dec 2016+6.9%
30 Dec 2016+5.6%
6 Jan 2017+6.7%
13 Jan 2017+5.0%
20 Jan 2017+2.2%
27 Jan 2017−1.2%
3 Feb 2017+0.9%
10 Feb 2017−6.6%
17 Feb 2017−7.7%
23 Feb 2017−14.9%
3 Mar 2017−11.7%
10 Mar 2017−12.9%
17 Mar 2017−14.6%
24 Mar 2017−13.1%
31 Mar 2017−17.3%
7 Apr 2017−20.3%
13 Apr 2017−15.4%
21 Apr 2017−15.8%
28 Apr 2017−20.5%
5 May 2017−24.3%
12 May 2017−23.2%
19 May 2017−17.8%
26 May 2017−31.1%
2 Jun 2017−30.2%
9 Jun 2017−29.5%
16 Jun 2017−28.4%
23 Jun 2017−34.4%
30 Jun 2017−30.9%
7 Jul 2017−26.2%
14 Jul 2017−28.0%
21 Jul 2017−26.4%
28 Jul 2017−27.0%
4 Aug 2017−27.8%
11 Aug 2017−26.5%
18 Aug 2017−32.9%
24 Aug 2017−14.1%
1 Sep 2017−18.8%
8 Sep 2017−19.9%
15 Sep 2017−16.4%
22 Sep 2017−8.9%
29 Sep 2017−7.5%
6 Oct 2017−10.6%
13 Oct 2017−10.2%
19 Oct 2017−11.1%
27 Oct 2017−10.0%
3 Nov 2017+0.0%
10 Nov 2017−20.1%
17 Nov 2017−17.9%
24 Nov 2017−23.9%
1 Dec 2017−21.7%
8 Dec 2017−20.2%
15 Dec 2017−18.5%
22 Dec 2017−22.0%
29 Dec 2017−23.1%
5 Jan 2018−22.3%
12 Jan 2018−21.6%
19 Jan 2018−20.9%
25 Jan 2018−12.9%
2 Feb 2018−20.8%
9 Feb 2018−2.4%
16 Feb 2018−1.6%
23 Feb 2018−2.7%
1 Mar 2018−3.1%
9 Mar 2018−4.9%
16 Mar 2018−9.1%
23 Mar 2018−9.0%
28 Mar 2018−10.8%
6 Apr 2018−5.9%
13 Apr 2018−11.0%
20 Apr 2018−9.6%
27 Apr 2018−11.9%
4 May 2018−5.3%
11 May 2018−10.3%
18 May 2018−9.6%
25 May 2018−7.3%
1 Jun 2018−5.2%
8 Jun 2018+2.3%
15 Jun 2018+16.1%
22 Jun 2018+17.3%
29 Jun 2018+20.0%
6 Jul 2018+12.9%
13 Jul 2018+10.1%
20 Jul 2018+0.8%
27 Jul 2018+0.3%
3 Aug 2018+7.7%
10 Aug 2018+4.3%
17 Aug 2018+12.4%
24 Aug 2018+14.8%
31 Aug 2018+13.9%
7 Sep 2018+12.4%
14 Sep 2018+1.3%
21 Sep 2018−2.8%
28 Sep 2018+0.2%
5 Oct 2018−2.2%
12 Oct 2018+4.0%
19 Oct 2018+16.9%
26 Oct 2018+17.0%
2 Nov 2018+4.0%
9 Nov 2018+13.6%
16 Nov 2018+6.1%
22 Nov 2018+3.6%
30 Nov 2018+4.0%
7 Dec 2018−2.8%
14 Dec 2018−5.7%
21 Dec 2018+0.1%
28 Dec 2018−7.1%
4 Jan 2019−6.2%
11 Jan 2019−4.6%
18 Jan 2019−7.8%
25 Jan 2019−5.7%
1 Feb 2019+2.1%
8 Feb 2019−3.8%
15 Feb 2019−8.6%
22 Feb 2019−9.0%
1 Mar 2019−10.5%
8 Mar 2019−10.4%
15 Mar 2019−11.4%
22 Mar 2019−18.0%
29 Mar 2019−17.6%
5 Apr 2019−11.9%
12 Apr 2019−7.1%
18 Apr 2019−9.6%
26 Apr 2019−7.3%
3 May 2019−7.7%
10 May 2019−2.2%
17 May 2019−8.5%
24 May 2019−10.8%
31 May 2019−13.7%
7 Jun 2019−12.0%
14 Jun 2019−9.7%
21 Jun 2019−4.9%
28 Jun 2019+2.1%
5 Jul 2019−6.4%
12 Jul 2019−6.3%
19 Jul 2019−6.1%
26 Jul 2019−5.4%
2 Aug 2019−4.8%
9 Aug 2019−6.6%
16 Aug 2019+0.5%
23 Aug 2019+6.4%
30 Aug 2019+7.8%
6 Sep 2019+14.2%
13 Sep 2019+12.1%
20 Sep 2019+9.8%
27 Sep 2019−2.3%
4 Oct 2019−0.8%
11 Oct 2019−4.8%
18 Oct 2019−3.0%
27 Oct 2019−8.1%
1 Nov 2019−8.6%
8 Nov 2019−12.3%
15 Nov 2019−5.8%
22 Nov 2019−5.5%
29 Nov 2019−1.3%
6 Dec 2019−9.8%
13 Dec 2019−9.1%
20 Dec 2019−5.4%
27 Dec 2019+2.0%
3 Jan 2020+3.8%
10 Jan 2020−0.7%
17 Jan 2020−3.0%
24 Jan 2020−6.1%
1 Feb 2020−9.2%
7 Feb 2020−4.8%
14 Feb 2020−6.4%
20 Feb 2020−12.3%
28 Feb 2020−14.2%
6 Mar 2020−6.6%
13 Mar 2020−3.3%
20 Mar 2020+11.0%
27 Mar 2020+0.4%
3 Apr 2020+17.6%
9 Apr 2020+29.5%
17 Apr 2020+32.0%
24 Apr 2020+44.2%
30 Apr 2020+36.7%
8 May 2020+42.5%
15 May 2020+42.0%
22 May 2020+53.1%
29 May 2020+51.2%
5 Jun 2020+44.4%
12 Jun 2020+50.1%
19 Jun 2020+25.1%
26 Jun 2020+46.9%
3 Jul 2020+6.2%
10 Jul 2020−9.5%
17 Jul 2020−7.7%
24 Jul 2020−23.9%
31 Jul 2020−1.8%
7 Aug 2020−16.4%
14 Aug 2020−1.8%
21 Aug 2020−17.1%
28 Aug 2020−11.0%
4 Sep 2020−8.3%
11 Sep 2020−9.1%
18 Sep 2020+5.0%
25 Sep 2020+0.8%
1 Oct 2020+5.4%
9 Oct 2020+8.9%
16 Oct 2020+7.7%
23 Oct 2020+8.5%
30 Oct 2020−7.9%
6 Nov 2020−4.9%
14 Nov 2020−23.7%
20 Nov 2020−22.5%
27 Nov 2020−19.8%
4 Dec 2020−18.3%
11 Dec 2020−21.2%
18 Dec 2020−29.3%
24 Dec 2020−26.0%
1 Jan 2021−25.0%
8 Jan 2021−21.4%
15 Jan 2021−18.9%
22 Jan 2021−12.4%
29 Jan 2021−7.1%
5 Feb 2021−5.7%
12 Feb 2021−4.2%
19 Feb 2021−1.5%
26 Feb 2021+0.5%
5 Mar 2021−3.5%
12 Mar 2021−1.0%
19 Mar 2021−5.1%
26 Mar 2021−7.0%
1 Apr 2021−5.2%
9 Apr 2021−1.1%
16 Apr 2021−6.5%
23 Apr 2021−2.4%
30 Apr 2021−3.3%
7 May 2021+9.5%
14 May 2021+12.2%
21 May 2021+15.0%
28 May 2021+11.0%
4 Jun 2021+12.4%
11 Jun 2021+9.5%
18 Jun 2021+6.3%
25 Jun 2021+6.3%
2 Jul 2021+4.9%
9 Jul 2021−1.7%
16 Jul 2021+0.0%
23 Jul 2021−3.3%
30 Jul 2021−7.0%
6 Aug 2021−14.9%
13 Aug 2021−29.9%
20 Aug 2021−31.7%
27 Aug 2021−30.4%
3 Sep 2021−31.5%
9 Sep 2021−29.6%
17 Sep 2021−30.0%
24 Sep 2021−31.8%
1 Oct 2021−28.0%
8 Oct 2021−31.1%
14 Oct 2021−34.5%
22 Oct 2021−34.7%
29 Oct 2021−27.1%
4 Nov 2021−29.0%
12 Nov 2021−13.7%
18 Nov 2021−12.8%
26 Nov 2021−6.3%
3 Dec 2021−10.6%
10 Dec 2021−12.1%
17 Dec 2021−5.6%
24 Dec 2021+0.4%
31 Dec 2021−1.5%
7 Jan 2022−3.2%
14 Jan 2022+0.8%
21 Jan 2022−0.3%
28 Jan 2022−0.1%
4 Feb 2022−4.7%
11 Feb 2022−11.4%
18 Feb 2022−10.7%
25 Feb 2022−15.4%
4 Mar 2022−12.8%
11 Mar 2022−9.3%
17 Mar 2022−12.8%
25 Mar 2022−15.7%
1 Apr 2022−20.1%
8 Apr 2022−14.6%
13 Apr 2022−15.0%
22 Apr 2022−14.6%
29 Apr 2022−17.6%
6 May 2022−10.8%
13 May 2022−3.2%
20 May 2022−11.3%
27 May 2022−16.1%
3 Jun 2022−14.6%
10 Jun 2022−14.1%
17 Jun 2022−10.2%
24 Jun 2022−7.7%
1 Jul 2022−6.7%
8 Jul 2022−8.9%
15 Jul 2022−8.2%
22 Jul 2022−11.5%
29 Jul 2022−12.7%
5 Aug 2022−13.0%
12 Aug 2022−14.3%
19 Aug 2022−1.7%
26 Aug 2022−1.4%
2 Sep 2022−1.0%
9 Sep 2022−4.2%
16 Sep 2022−11.5%
23 Sep 2022−10.0%
30 Sep 2022−2.5%
7 Oct 2022+4.8%
14 Oct 2022+0.3%
21 Oct 2022+1.0%
28 Oct 2022+4.2%
4 Nov 2022+2.1%
11 Nov 2022+6.0%
18 Nov 2022+2.6%
25 Nov 2022+6.4%
2 Dec 2022+13.7%
9 Dec 2022+10.2%
16 Dec 2022+12.8%
23 Dec 2022+16.8%
30 Dec 2022+3.7%
6 Jan 2023+0.8%
13 Jan 2023+5.8%
20 Jan 2023+9.5%
27 Jan 2023+9.0%
3 Feb 2023+7.7%
10 Feb 2023+2.7%
17 Feb 2023−3.5%
24 Feb 2023−1.4%
3 Mar 2023−7.1%
10 Mar 2023−5.5%
17 Mar 2023−2.1%
24 Mar 2023−10.3%
31 Mar 2023−5.9%
6 Apr 2023−6.7%
13 Apr 2023−8.6%
21 Apr 2023−4.7%
28 Apr 2023−6.7%
5 May 2023−6.9%
12 May 2023+1.9%
19 May 2023+12.9%
26 May 2023+11.0%
2 Jun 2023+16.2%
9 Jun 2023+14.8%
16 Jun 2023+14.2%
23 Jun 2023+22.0%
30 Jun 2023+26.4%
7 Jul 2023+23.4%
14 Jul 2023+26.5%
21 Jul 2023+20.9%
28 Jul 2023+25.9%
4 Aug 2023+40.5%
11 Aug 2023+30.3%
18 Aug 2023+29.1%
25 Aug 2023+31.0%
1 Sep 2023+25.9%
8 Sep 2023+29.8%
15 Sep 2023+29.4%
22 Sep 2023+20.1%
29 Sep 2023+24.5%
6 Oct 2023+23.9%
13 Oct 2023+23.9%
20 Oct 2023+24.1%
27 Oct 2023+17.3%
3 Nov 2023+10.9%
12 Nov 2023+7.1%
17 Nov 2023+7.0%
24 Nov 2023+10.5%
1 Dec 2023+12.4%
8 Dec 2023+2.9%
15 Dec 2023−0.1%
22 Dec 2023+4.9%
29 Dec 2023+0.6%
5 Jan 2024+7.0%
12 Jan 2024+4.1%
20 Jan 2024+5.7%
25 Jan 2024+12.8%
2 Feb 2024+9.5%
9 Feb 2024+21.9%
16 Feb 2024+20.9%
23 Feb 2024+14.8%
2 Mar 2024+13.7%
7 Mar 2024+25.5%
15 Mar 2024+27.8%
22 Mar 2024+22.2%
28 Mar 2024+18.0%
5 Apr 2024+9.4%
12 Apr 2024+11.0%
19 Apr 2024+5.7%
26 Apr 2024+3.7%
3 May 2024+4.8%
10 May 2024−3.4%
18 May 2024−2.0%
24 May 2024−5.8%
31 May 2024−6.9%
7 Jun 2024−8.9%
14 Jun 2024−14.0%
21 Jun 2024−14.1%
28 Jun 2024−11.1%
5 Jul 2024−0.3%
12 Jul 2024−0.5%
19 Jul 2024+3.3%
26 Jul 2024+2.1%
2 Aug 2024+7.6%
9 Aug 2024+19.4%
16 Aug 2024+16.2%
23 Aug 2024+20.7%
30 Aug 2024+29.1%
6 Sep 2024+30.6%
13 Sep 2024+33.0%
20 Sep 2024+29.0%
27 Sep 2024+28.3%
4 Oct 2024+21.8%
11 Oct 2024+21.5%
18 Oct 2024+19.4%
25 Oct 2024+20.6%
1 Nov 2024+13.9%
8 Nov 2024+0.8%
14 Nov 2024+1.4%
22 Nov 2024+4.0%
29 Nov 2024−4.0%
6 Dec 2024−4.7%
13 Dec 2024−5.6%
20 Dec 2024+7.7%
27 Dec 2024+8.8%
3 Jan 2025+11.3%
10 Jan 2025+6.2%
17 Jan 2025+4.5%
24 Jan 2025+4.2%
1 Feb 2025−1.0%
7 Feb 2025+9.0%
14 Feb 2025+3.8%
21 Feb 2025−1.1%
28 Feb 2025+5.2%
7 Mar 2025+7.5%
13 Mar 2025+8.4%
21 Mar 2025+3.0%
28 Mar 2025−4.0%
4 Apr 2025−8.4%
11 Apr 2025−5.3%
17 Apr 2025−8.3%
25 Apr 2025−7.9%
2 May 2025−1.9%
9 May 2025−7.6%
16 May 2025−5.8%
23 May 2025−6.2%
30 May 2025−11.9%
6 Jun 2025−14.8%
13 Jun 2025−11.9%
20 Jun 2025−16.2%
27 Jun 2025−15.3%
4 Jul 2025−12.8%
11 Jul 2025−16.0%
18 Jul 2025−7.6%
25 Jul 2025−8.7%
1 Aug 2025−12.3%
8 Aug 2025−9.4%
14 Aug 2025−4.3%
22 Aug 2025−1.1%
29 Aug 2025−1.7%
5 Sep 2025−1.3%
12 Sep 2025+1.0%
19 Sep 2025+3.6%
26 Sep 2025+3.0%
3 Oct 2025+1.9%
10 Oct 2025+3.2%
17 Oct 2025−1.0%
24 Oct 2025−3.9%
31 Oct 2025+0.6%
7 Nov 2025−2.0%
14 Nov 2025−0.3%
21 Nov 2025−0.7%
28 Nov 2025+3.3%
5 Dec 2025+3.6%
12 Dec 2025+1.1%
19 Dec 2025+2.6%
26 Dec 2025+5.3%
2 Jan 2026+2.0%
9 Jan 2026+10.8%
16 Jan 2026+12.7%
23 Jan 2026+14.8%
1 Feb 2026+11.4%
6 Feb 2026+10.6%
13 Feb 2026+9.2%
20 Feb 2026+11.0%
27 Feb 2026+13.8%
6 Mar 2026+17.4%
13 Mar 2026+19.3%
20 Mar 2026+19.2%
27 Mar 2026+22.1%
2 Apr 2026+21.2%
10 Apr 2026+11.7%
17 Apr 2026+9.4%
24 Apr 2026+8.0%
30 Apr 2026+9.7%
8 May 2026+10.8%
15 May 2026+6.9%
22 May 2026+6.0%
29 May 2026+0.7%
4 Jun 2026−3.9%
5 Jun 2026−7.1%
9 Jun 2026−8.5%
10 Jun 2026−11.3%
12 Jun 2026−7.1%
17 Jun 2026−6.2%
19 Jun 2026−0.1%
24 Jun 2026+0.7%
25 Jun 2026−0.2%
1 Jul 2026+0.0%
3 Jul 2026+5.4%
10 Jul 2026+6.3%
17 Jul 2026+4.7%
24 Jul 2026+3.4%
31 Jul 2026+2.1%
7 Aug 2026−0.5%
14 Aug 2026−4.9%
21 Aug 2026−8.1%
28 Aug 2026−6.1%
4 Sep 2026−10.7%
11 Sep 2026−10.4%
18 Sep 2026−9.9%
25 Sep 2026−9.7%
1 Oct 2026−11.8%
9 Oct 2026−15.3%
16 Oct 2026−15.1%
23 Oct 2026−12.1%
30 Oct 2026−10.1%
6 Nov 2026−14.8%
8 Nov 2026−10.1%
13 Nov 2026−10.9%
18 Nov 2026−10.1%
Each bar is one week, from 2016 to now (555 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the NIFTY 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 11 years the share price moved +14% while the NIFTY 500 moved +306%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 31 July 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What changed at Lupin this quarter?

Three changes stood out: profit fell in the September 2026 quarter, revenue up on a year earlier for 13 quarters in a row (every quarter we can compare) and foreign funds (FIIs) raised their stake for 4 quarters in a row.

  1. Profit fell in the September 2026 quarter

    Profit was ₹1,155 crore, -22.2% on a year earlier (₹1,485 crore), after 12 quarters of growth.

    Why: Profit fell because other operating income, money from export incentives, dropped sharply.

    Next results: check whether competition, research spending and input costs pull margins down in the second half.

    From the earnings call on 4 Nov 2026.

  2. Revenue up on a year earlier for 13 quarters in a row (every quarter we can compare)

    In the September 2026 quarter revenue was ₹7,827 crore, +11.1% on a year earlier.

    Why: Revenue rose because sales in other developed markets, led by Australia and Canada, jumped.

    Next results: check whether India sales keep growing faster than the overall Indian pharma market, helped by breathing and heart drugs.

    From the earnings call on 4 Nov 2026.

  3. Foreign funds (FIIs) raised their stake for 4 quarters in a row

    From 20.5% to 23.3% of the company by the September 2026 quarter.

What are Lupin's latest quarterly results?

For July to September 2026 (the quarter ended 30 September 2026), Lupin reported revenue of ₹7,827 crore, up 11.1% from ₹7,048 crore a year earlier, and a profit of ₹1,155 crore, down 22.2% from ₹1,485 crore.

Lupin results: July to September 2026 against a year earlier

Lupin results: July to September 2026 against a year earlier
MeasureJuly to September 2026July to September 2025Change
Revenue₹7,827 crore₹7,048 crore+11.1%
Profit₹1,155 crore₹1,485 crore−22.2%
Earnings per share₹25.26₹32.36−21.9%
Operating margin26.1%33.2%−7.1 points

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Lupin's management discussed these results on a call held on 4 November 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

What is the Lupin share price history?

Lupin closed at ₹1,971.90 on 18 November 2026, down 2.8% from ₹2,029.40 a year earlier (21 November 2025) and up 119.4% over five years. Its highest weekly close since February 2016 was ₹2,496.30 on 10 July 2026.

Lupin share price: then and now

Lupin share price: then and now
WhenCloseChange to 18 Nov 2026
1 week ago · 11 Nov 2026₹2,023.40−2.5%
1 month ago · 19 Oct 2026₹1,939.20+1.7%
6 months ago · 15 May 2026₹2,276.20−13.4%
1 year ago · 21 Nov 2025₹2,029.40−2.8%
3 years ago · 17 Nov 2023₹1,196.30+64.8%
5 years ago · 18 Nov 2021₹898.70+119.4%
10 years ago · 18 Nov 2016₹1,417.75+39.1%
Earliest weekly close in our records · 26 Feb 2016₹1,726.75+14.2%
Highest weekly close since February 2016, also the 52-week high · 10 Jul 2026₹2,496.30−21.0%
Lowest weekly close since February 2016 · 27 Mar 2020₹548.10+259.8%
52-week low (weekly close) · 23 Oct 2026₹1,928.90+2.2%

Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

568 weekly closes from 26 February 2016 to 18 November 2026.

What is the latest news on Lupin?

18 Nov 2026: Lupin closed at ₹1,971.90, down 2.5% on the week and up 1.7% on the month. 4 Nov 2026: Lupin held its results call for July to September 2026. Management guided: FY27 US revenues 1.1-1.2 billion dollars and operating margin 24-25% with H2 moderation flagged.

Earlier

  • Results for July to September 2026: Revenue up 11.1% and profit down 22.2% on a year earlier.
  • 17 Jul 2026: ex-date for a dividend of ₹18 a share.

What dividend does Lupin pay?

Lupin paid ₹18 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.91% at the ₹1,971.90 close on 18 November 2026. The last was a dividend of ₹18 a share, ex-date 17 July 2026.

Lupin dividends since 1 April 2021

Lupin dividends since 1 April 2021
Ex-dateDividend per shareTypeRecord date
17 Jul 2026Dividend₹18Dividendsame day
25 Jul 2025Dividend₹12Dividendsame day
16 Jul 2024Dividend₹8Dividendsame day
14 Jul 2023Dividend₹4Dividendsame day
14 Jul 2022Dividend₹4Dividend15 Jul 2022
27 Jul 2021Dividend₹6.50Dividend28 Jul 2021

Amounts as the company declared them on the exchange. A dividend goes to whoever owns the shares before the ex-date.

5 of 5Of the last 5 financial years, years with an exchange dividend record

Yes. Lupin Ltd paid out 15% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years. 2 of those years show a negative figure because profit itself was negative.

From the exchange corporate-actions record, read 18 November 2026.

What did Lupin management say on the latest results call?

On the call for July to September 2026, held on 4 November 2026, Lupin's management guided: FY27 US revenues 1.1-1.2 billion dollars and operating margin 24-25% with H2 moderation flagged.

“give us the confidence that we should be able to evolve our developed-market business into a more durable, more sustainable portfolio going forward, as opposed to the one-off exclusives.”Vinita, closing remarks, on the call for July to September 2026

What management guided

  • H2 organic growth around 20% ex-US; India formulations 1.2-1.3 times IPM.
  • Full-year R&D around 8% focused on complex and specialty platforms.
  • Full-year ETR 27-28% with H1 at 28.5%.
  • More than 15 US submissions in FY27; more than 60 launches next 3 years including 25 injectable, respiratory, 5 biosimilars and 2-3 505(b)(2)s.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 4 November 2026.

What to watch in Lupin's next results?

When Lupin reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Tolvaptan entrant tally and pricing versus share erosion into next print with flagged further competition.

Management raised each of these on the latest results call.

  • Tolvaptan entrant tally and pricing versus share erosion into next print with flagged further competition.
  • Apixaban final approval progress toward guided launch window with planned-channel traction and share build check.
  • India growth multiple versus IPM with respiratory pickup, cardiac bounce and chronic mix check.

Which stock lists is Lupin on?

Lupin is on 3 of our India lists: 52 week high & low, Small & mid cap stocks and Pharma stocks.

Is Lupin profitable?

Lupin Ltd earned ₹1,155 Cr of net profit in the Sep 2026 quarter, −22.2% on the same quarter a year earlier. Full-year FY26 profit was ₹5,355 Cr. Over 10 years profit has grown 9.0% a year on average. The Sep 2026 quarter's profit is 14.8% of that quarter's revenue. The same quarter a year earlier earned ₹1,485 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was ₹5,355 Cr (+62.0% on the year before).

Why profit moved: revenue changed +11.1% on a year earlier and the margin moved −7.1 percentage points. Sales did the work while the margin got thinner.

On average over the last four quarters, profit changed +29.8% and revenue +24.9%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

How much revenue does Lupin make, and is it growing?

Lupin Ltd reported ₹7,827 Cr of revenue in the Sep 2026 quarter, +11.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 7.0% a year on average. The last full year, FY26, came in at ₹27,958 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹30,747 Cr.

FY26 revenue was ₹27,958 Cr, +23.1% on the year before.

Recent pace: the last four quarters grew +24.9% on average, against 7.0% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +24.2%, against +19.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +20.1%, against +40.3% a year (rolling over).

How much of every ₹100 of sales does Lupin keep?

Lupin Ltd's operating margin was 26.1% in the Sep 2026 quarter, 7.1 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 1.3% and 29.2%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why this happened. Emerging-markets sales rose on Brazil, South Africa and the Philippines, while Europe benefited from VISUfarma consolidation. This reduces dependence on a single US exclusivity product, but these businesses must keep converting launches into recurring revenue.

Why the margin moved: operating margin changed −7.1 percentage points on the year while gross margin changed +0.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Watch next

Metric
International growth diversification
Threshold
Brazil's metabolic launches fail to sustain growth or VISUfarma does not convert its new distribution footprint into sales.
Which result
the next result

Is Lupin's profit turning into cash?

Over the last 3 years, 132% of Lupin Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹7,334 Cr of operating cash against ₹5,355 Cr of profit. After ₹2,055 Cr of spending on assets, ₹5,280 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 132% of profit came in as cash: the cash cycle got 68 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Where does Lupin's cash go?

Lupin Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 181 days in FY26, down from 249 days in FY21. It spent ₹4,666 Cr on assets over the last 3 years. Customers take 86 days to pay, and stock sits for 303 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹27,958 Cr, each day of that cycle ties up about ₹76.6 Cr, so roughly ₹13,864 Cr is tied up in the business at any time.

FY26: customers took 86 days to pay and stock sat for 303 days, about 10.0 months of sales sitting as stock, for a full cycle of 181 days, shorter than FY21's 249.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 303 days. Customers pay about 86 days after that. Suppliers are paid at 208 days. Together that makes the 181-day cycle.

Spending on assets: ₹4,666 Cr over the last 3 years, against ₹3,742 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹1,016 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

What is Lupin's P/E ratio, and how does it compare with its own history?

Lupin Ltd's P/E is 17.3×, near the low end of its own history: it has been lower only 4% of the time. Its usual P/E (the middle reading) is 29.2×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹113.88.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.

17.3×P/E · lower than 96% of its last 11 years
n/mPEG · 3-year earnings growth is negative

Why the multiple is where it is: over the past year earnings per share moved +20.2% while the price moved −2.8%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 3 years the price moved +18.1% a year; about +57.3% a year came from earnings growth and about −39.2 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

What growth does the Lupin share price assume?

Worked out from its price on 24 August 2026, Lupin Ltd's share price assumed profit growth of about 9.1% a year. Over the past 10 years its profit actually grew 9.0% a year. Today its P/E is 17.3×, lower than 96% of its own last 11 years.

This works the share price backwards. It asks one question: what yearly profit growth does the price already assume? The answer is the growth rate at which eleven years of profit (six years of growth, then five years of slowing) add up to that day's market value, after each year is discounted at 11%.

This is a one-day reading, taken on 24 August 2026. Every other number on this page, the multiple included, uses the latest price as of 18 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements.

Is the Lupin business getting better or worse?

Lupin Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +334.8% at its peak to +20.1%, but the business is still expanding, with ROCE steady at 26.7% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Steady highRevenue growth · latest (Sep 2026) +24.2%, range +12.4% to +28.2%
Turning downProfit growth · latest (Sep 2026) +20.1%, range +20.1% to +334.8%
Turning downEPS growth · latest (Sep 2026) +20.2%, range +20.2% to +345.1%
Steady highROCE · latest (four quarters to Sep 2026) 26.7%, range 18.2% to 34.5%

Why it matters: when the lines disagree, each line above matters more than any single label.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue+23.1%+18.9%+13.0%+7.0%
Profit+62.0%+128.6%+34.2%+9.0%
EPS+62.3%+131.1%+34.2%+8.8%
Share price−2.8%+18.1%+17.0%+3.4%
+11.1%Revenue growth (Sep 2026) · latest quarter against a year ago
−22.2%Profit growth (Sep 2026) · latest quarter against a year ago
7.0%Revenue, 10 years · yearly growth over the long run

What is the Lupin story, and has it been checked?

Lupin Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: mid expansion with peak margin risk. Still open: A sustained operating margin below management's FY27 framework after Tolvaptan competition, without a measurable launch offset from Pegfilgrastim or other complex products, would break the thesis.

NOT YET CHECKED

From the numbers. The operating cycle remains in expansion rather than…

From the price. Price stage 4, week 7, below its 200-day line, relative strength falling.

Where they disagree. The operating cycle remains in expansion rather than a confirmed trough.

What is not proven yet. A sustained operating margin below management's FY27 framework after Tolvaptan competition, without a measurable launch offset from Pegfilgrastim or other complex products, would break the thesis.

The test written in advance. US competition and product erosion. Measured by: US competition and product erosion by the next result.

What the company does. The latest quarter extended revenue growth while reported profit grew more slowly because tax rose and operating margin eased from the preceding peak.

The key numbers to watch, and the level that would change the picture

The key numbers to watch, and the level that would change the picture
MeasureNowWhy it mattersWhat to watch
International growth diversificationHIGHBrazil-led emerging markets and other developed markets broaden growth beyond the US portfolio.Brazil's metabolic launches fail to sustain growth or VISUfarma does not convert its new distribution footprint into sales.
Complex-product pipelineHIGHRespiratory, injectables, biosimilars and 505(b)(2) programs are intended to replace fading US exclusivity economics.Regulatory remediation delays approvals or launch dates move beyond the period in which Tolvaptan revenue is falling.
India chronic and metabolic franchiseMEDIUMChronic mix, diabetes launches and prescription growth provide a domestic counterweight to US volatility.Core prescription growth falls below the market after new-product launches and the chronic mix ceases rising.
Cash-funded reinvestmentMEDIUM—Operating cash flow falls below profit while payable days reverse or development spending rises without launch conversion.

Everything further down this page is evidence for or against these.

The pricefalling, below the 200-day averageFY26-Q2 to FY27-Q1
The whymultiple below its usual level, earnings risingFY26-Q2 to FY27-Q1

FY26-Q2FY27-Q1

What the surface reading misses. The surface reading is: A 30% operating margin reads as sustained high profitability. The research reads it further: The normalized analysis places current operating margin above the through-cycle estimate, while management cites competition, development spending and cost inflation as prospective pressures.

  • 1 · Operating leveragebuilding
  • 2 · Value-added mixbuilding
  • 3 · Management changebuilding
  • 4 · Paying down debtbuilding
  • 5 · Regulatory approvalquiet
  • 6 · Order-book winsquiet
  • 7 · Consolidationquiet
  • 8 · Demerger or value unlockquiet
  • 9 · Buybackquiet
  • 10 · New geographiesquiet
  • 11 · More business from existing customersquiet
  • 12 · New product launchquiet
  • 13 · Mandatory normsquiet
  • 14 · A bigger market to servequiet
  • 15 · Market-share gainsquiet
  • 16 · Asset qualityquiet

Lever 1 · Operating leverage: building. Brazil-led emerging markets and other developed markets broaden growth beyond the US portfolio. What proves it keeps working: International growth diversification. It stops working if Brazil's metabolic launches fail to sustain growth or VISUfarma does not convert its new distribution footprint into sales.

Lever 2 · Value-added mix: building. Respiratory, injectables, biosimilars and 505(b)(2) programs are intended to replace fading US exclusivity economics. What proves it keeps working: Complex-product pipeline. It stops working if Regulatory remediation delays approvals or launch dates move beyond the period in which Tolvaptan revenue is falling.

Lever 3 · Management change: building. Chronic mix, diabetes launches and prescription growth provide a domestic counterweight to US volatility. What proves it keeps working: India chronic and metabolic franchise. It stops working if Core prescription growth falls below the market after new-product launches and the chronic mix ceases rising.

Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

The whole page in one table. Each row links to its section.

The whole page in one table. Each row links to its section.
SectionWhere it is nowThe one thing to watch next
Margin26%International growth diversification
Ownershipsee the sectionIndia chronic and metabolic franchise
Debtsee the sectionCash-funded reinvestment

Did Lupin management deliver what it promised?

What Lupin Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

US FY28 Growth Outlook Softened · 4 November 2026. In Aug 2026, management said the U.S. business would return to a growth trajectory from FY28. In Nov 2026, management instead said it hoped only to maintain at least USD 1 billion plus and acknowledged it might not match FY27, moving the next explicit growth expectation to FY29; the additional competition cited in the latest call was not reconciled with the earlier growth forecast.

FY27 ETR Guidance Changed Without Reconciliation · 4 November 2026. In May 2026, management guided FY27 ETR to 25%-26%, while the Nov 2026 call stated 27%-28%, a two-point increase in the expected tax burden that affects earnings conversion. The latest call did not reconcile this higher range with the earlier guidance; the same 27%-28% range had appeared in Aug 2026, so this is an unreconciled change carried forward rather than a new Nov 2026 revision.

FY27 Tax Rate Guidance Raised · 7 August 2026. In May 2026, management guided to a 25%-26% FY27 effective tax rate and explicitly cited the phase-out of incentives. In August 2026, management raised the range to 27%-28% without explaining what changed, creating a material adverse revision to earnings expectations.

Dulera Launch Timing Becomes Conditional · 7 August 2026. In May 2026, management expected Dulera to be in the market in FY28. In August 2026, FY28 became only a possibility and FY29 was introduced as the fallback, with no explanation for the timeline slippage.

Every quote above is taken word for word from the company’s own earnings calls.

What is Lupin management's track record?

Strong quantitative delivery through the US generics cycle, but one material said-vs-delivered credibility flag.

0%Promoter shares pledged

Checked 21 July 2026.

How much does Lupin earn on its capital?

Lupin Ltd earned a ROCE of 30% in FY26. That is up from a low of −7% in FY22. Its return on capital used (ROIC) is 12.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 19.2% net margin and 0.73× asset turnover (sales divided by assets).

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

Why the return is what it is (FY26): a 19.2% net margin × 0.73× asset turnover × 1.70× leverage (assets divided by equity) ≈ 23.8% on equity. The margin does most of the work; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 24.3% − 12.0% = +12.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value.

The 24.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 26.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Does Lupin have too much debt?

Lupin Ltd has total debt of ₹6,180 Cr against shareholder equity of ₹24,050 Cr as of Sep 2026, so its debt is 0.26× its equity, which is very little. Year by year, that ratio went from 0.34 in FY22 to 0.29 in FY26. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Why this happened. The multi-year cash record supports reinvestment, though payable-led cash-cycle improvement means cash quality should be monitored alongside reported profit.

Watch next

Metric
Cash-funded reinvestment
Threshold
Operating cash flow falls below profit while payable days reverse or development spending rises without launch conversion.
Which result
the next result

What is the Lupin shareholding pattern?

Foreign institutions raised their stake in Lupin Ltd by 1.8 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 23.3% of the company. Domestic institutions moved −1.3 points over the same period, to 23.8%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Why this happened. India sales grew faster than the India pharmaceutical market in the latest quarter, led by diabetes and a higher chronic mix. The chronic-therapy annuity premium applies if launch-led growth remains durable rather than being confined to an initial product burst.

Over the last two years: Foreign institutions: +1.8 points over 8 quarters, to 23.3%; Domestic institutions: −1.3 points over 8 quarters, to 23.8%; Promoters: −0.1 points over 8 quarters, to 46.8%.

Why the owners changed: foreign institutions drove it (+1.8 points), with the other side taken by domestic institutions (−1.3 points). They raised their stake step by step.

Watch next

Metric
India chronic and metabolic franchise
Threshold
Core prescription growth falls below the market after new-product launches and the chronic mix ceases rising.
Which result
the next result

How far is Lupin from balance-sheet trouble?

For Lupin Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

How does Lupin rank in its industry?

57.2 out of 100, rank 15 of 44 in Pharma - Formulators, with 90% of the evidence available.

Lupin Ltd scores 57.2 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 15. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 20.8 + 20.2 + 14.7 + 1.5 = 57.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is Lupin compared with?

Lupin ranks 15 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 57.2 out of 100.

  1. 1Marksans Pharma LtdMARKSANS · losing its lead · Most evidence points up · 78% evidence75.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidenceCapital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidenceValuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidenceRelative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks aheadExact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  2. 2Emcure Pharmaceuticals LtdEMCURE · leader · Most evidence points up · 75% evidence72.8out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidenceCapital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidenceValuation 10.0/20 · P/E 40.5× · PEG — · 15% evidenceRelative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks aheadExact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  3. 3Kwality Pharmaceuticals LtdKPL · breaking out · Most evidence points up · 75% evidence68.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidenceCapital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidenceValuation 6.5/20 · P/E 45.5× · PEG — · 50% evidenceRelative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks aheadExact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  4. 4Rubicon Research LtdRUBICON · losing its lead · Most evidence points up · 87% evidence67.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidenceCapital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidenceValuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidenceRelative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks aheadExact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks.
  5. 5Accent Microcell LtdACCENTMIC · losing its lead · Most evidence points up · 65% evidence66.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.8/35 · Revenue — · Profit — · Operating margin change 7 points · 27% evidenceCapital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidenceValuation 10.1/20 · P/E 25.6× · PEG — · 50% evidenceRelative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks aheadExact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  6. 6Ajanta Pharma LtdAJANTPHARM · quiet · Most evidence points up · 100% evidence65.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidenceCapital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidenceValuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidenceRelative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks aheadExact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%.
  7. 7Mankind Pharma LtdMANKIND · turning · Most evidence points up · 100% evidence65.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidenceCapital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidenceValuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidenceRelative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks aheadExact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  8. 8Bliss GVS Pharma LtdBLISSGVS · leader · Most evidence points up · 82% evidence65.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidenceCapital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidenceValuation 6.5/20 · P/E 44.8× · PEG — · 50% evidenceRelative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks aheadExact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  9. 9Alembic Pharmaceuticals LtdAPLLTD · leader · Evidence leans up · 85% evidence64.0out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidenceCapital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidenceValuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidenceRelative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) — · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks aheadExact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  10. 10Ipca Laboratories LtdIPCALAB · leader · Evidence leans up · 82% evidence62.4out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidenceCapital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidenceValuation 11.7/20 · P/E 33.5× · PEG — · 50% evidenceRelative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks aheadExact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  11. 11Fredun Pharmaceuticals LtdFREDUN · losing its lead · Evidence leans up · 70% evidence61.2out of 100GrowthCapitalValuationRelative
  12. 12FDC LtdFDC · turning · Evidence leans up · 75% evidence59.2out of 100GrowthCapitalValuationRelative
  13. 13Aurobindo Pharma LtdAUROPHARMA · leader · Evidence leans up · 100% evidence58.9out of 100GrowthCapitalValuationRelative
  14. 14Corona Remedies LtdCORONA · breaking out · Evidence leans up · 73% evidence58.3out of 100GrowthCapitalValuationRelative
  15. 15Lupin Ltd this pageLUPIN · quiet · Evidence leans up · 90% evidence57.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 20.8/35 · Revenue 24.2% · Profit 20.1% · Operating margin change -7 points · 100% evidenceCapital efficiency 20.2/25 · ROCE 29.9% (year to Mar 2026) · Operating margin 26.1% · 100% evidenceValuation 14.7/20 · P/E 17.3× · PEG — · 50% evidenceRelative strength 1.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -25.2% · Strength vs NIFTY 500 (same reading) -13.6% · 1 year -2.8% · 100% evidence · 0 of 12 weeks aheadExact sum: 20.8 + 20.2 + 14.7 + 1.5 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  16. 16Gufic BioSciences LtdGUFICBIO · leader · Evidence leans up · 75% evidence56.8out of 100GrowthCapitalValuationRelative
  17. 17ERIS Lifesciences LtdERIS · basing · Evidence leans up · 67% evidence56.0out of 100GrowthCapitalValuationRelative
  18. 18Kilitch Drugs (India) LtdKILITCH · turning · Evidence leans up · 82% evidence55.8out of 100GrowthCapitalValuationRelative
  19. 19Caplin Point Laboratories LtdCAPLIPOINT · quiet · Evidence leans up · 90% evidence55.2out of 100GrowthCapitalValuationRelative
  20. 20Wockhardt LtdWOCKPHARMA · losing its lead · Evidence leans up · 83% evidence54.7out of 100GrowthCapitalValuationRelative
  21. 21Influx Healthtech LtdINFLUX · quiet · Evidence leans up · 63% evidence54.3out of 100GrowthCapitalValuationRelative
  22. 22Amrutanjan Health Care LtdAMRUTANJAN · breaking out · Evidence leans up · 90% evidence54.1out of 100GrowthCapitalValuationRelative
  23. 23Akums Drugs & Pharmaceuticals LtdAKUMS · losing its lead · Evidence leans up · 75% evidence53.3out of 100GrowthCapitalValuationRelative
  24. 24Strides Pharma Science LtdSTAR · breaking out · Evidence leans up · 82% evidence52.3out of 100GrowthCapitalValuationRelative
  25. 25Zydus Lifesciences LtdZYDUSLIFE · breaking out · Evidence leans up · 90% evidence51.5out of 100GrowthCapitalValuationRelative
  26. 26Glenmark Pharmaceuticals LtdGLENMARK · breaking out · Evidence leans up · 90% evidence50.6out of 100GrowthCapitalValuationRelative
  27. 27Bafna Pharmaceuticals LtdBAFNAPH · breaking out · Evidence leans down · 68% evidence49.1out of 100GrowthCapitalValuationRelative
  28. 28Alkem Laboratories LtdALKEM · quiet · Evidence leans down · 82% evidence48.3out of 100GrowthCapitalValuationRelative
  29. 29J B Chemicals & Pharmaceuticals LtdJBCHEPHARM · Too little evidence to rank firmly · 59% evidence45.8out of 100GrowthCapitalValuationRelative
  30. 30Bharat Parenterals LtdBPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence45.8out of 100GrowthCapitalValuationRelative
  31. 31Zim Laboratories LtdZIMLAB · leader · Evidence leans down · 74% evidence42.8out of 100GrowthCapitalValuationRelative
  32. 32Bajaj Healthcare LtdBAJAJHCARE · basing · Evidence leans down · 90% evidence42.7out of 100GrowthCapitalValuationRelative
  33. 33Lincoln Pharmaceuticals LtdLINCOLN · quiet · Evidence leans down · 90% evidence41.5out of 100GrowthCapitalValuationRelative
  34. 34Sun Pharmaceutical Industries LtdSUNPHARMA · quiet · Evidence leans down · 100% evidence39.8out of 100GrowthCapitalValuationRelative
  35. 35RPG Life Sciences LtdRPGLIFE · losing its lead · Evidence leans down · 90% evidence38.9out of 100GrowthCapitalValuationRelative
  36. 36Indoco Remedies LtdINDOCO · turning · Too little evidence to rank firmly · 52% evidence37.8out of 100GrowthCapitalValuationRelative
  37. 37Suven Life Sciences LtdSUVEN · quiet · Most evidence points down · 67% evidence34.4out of 100GrowthCapitalValuationRelative
  38. 38Torrent Pharmaceuticals LtdTORNTPHARM · quiet · Most evidence points down · 100% evidence34.2out of 100GrowthCapitalValuationRelative
  39. 39Natco Pharma LtdNATCOPHARM · quiet · Most evidence points down · 90% evidence31.9out of 100GrowthCapitalValuationRelative
  40. 40Dr Reddys Laboratories LtdDRREDDY · breaking out · Most evidence points down · 100% evidence30.4out of 100GrowthCapitalValuationRelative
  41. 41Cipla LtdCIPLA · quiet · Most evidence points down · 100% evidence27.9out of 100GrowthCapitalValuationRelative
  42. 42Biocon LtdBIOCON · basing · Most evidence points down · 100% evidence22.7out of 100GrowthCapitalValuationRelative
  43. 43Syncom Healthcare LtdSYNCOM · Too little evidence to rank firmly · 17% evidence42.4out of 100GrowthCapitalValuationRelative
  44. 44Sai Parenterals LtdSAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence38.3out of 100GrowthCapitalValuationRelative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - Formulators, all 44 compared on one page.

Which companies are close to Lupin in size?

Lupin is the 8th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Cipla, Mankind Pharma and Aurobindo Pharma. Just below it: Glenmark Pharmaceuticals, Alkem Laboratories and Biocon.

Pharma - Formulators companies close in size

  1. Cipla Ltd ₹1,14,478 crore
  2. Mankind Pharma Ltd ₹1,08,424 crore
  3. Aurobindo Pharma Ltd ₹1,03,355 crore
  4. Lupin Ltd ₹90,174 crore
  5. Glenmark Pharmaceuticals Ltd ₹74,679 crore
  6. Alkem Laboratories Ltd ₹62,443 crore
  7. Biocon Ltd ₹58,987 crore

All 44 Pharma - Formulators companies, largest first

Companies close in size in other industries

  1. Coforge Ltd ₹90,783 crore · IT - Software
  2. Manipal Health Enterprises Ltd ₹90,610 crore · Hospitals
  3. Lupin Ltd ₹90,174 crore
  4. Shree Cement Ltd ₹89,606 crore · Cement
  5. Federal Bank Ltd ₹89,124 crore · Banks - Private

What else do people ask about Lupin?

What is Lupin's share price today?

Lupin Ltd's share price is ₹1,971.90, −2.8% over the past year. The whole company is worth ₹90,188 Cr on the market.

In the last 52 weeks it traded between ₹1,929 to ₹2,496; today it is 8% of the way up from the low, 8.7% below its 200-day average (as of 18 November 2026).

What were Lupin's latest quarterly results?

Lupin Ltd reported revenue of ₹7,827 Cr and net profit of ₹1,155 Cr for the Sep 2026 quarter. Revenue rose 11.1% and profit fell 22.2% compared with a year earlier. Earnings per share were ₹25.26.

The operating margin was 26.1%, 7.1 percentage points lower than a year earlier (as of 18 November 2026).

What is Lupin's market cap?

Lupin Ltd's market capitalisation is ₹90,188 Cr at a share price of ₹1,971.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026).

How is Lupin performing?

Lupin Ltd's share price has been falling for 7 weeks. In its latest quarter, revenue rose 11.1% and profit fell 22.2% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 17 weeks running (as of 18 November 2026).

Will Lupin's share price go up?

This page does not forecast Lupin Ltd's share price. What it shows instead: the share price is ₹1,971.90, and it has been falling for 7 weeks. Its P/E of 17.3× is higher than 4% of its own last 11 years (as of 18 November 2026).

Who owns Lupin?

Promoters own 46.8% of Lupin Ltd, foreign institutions 23.3%, domestic institutions 23.8% and the public 6.1% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 1.8 percentage points over 8 quarters (as of 18 November 2026).

Where is Lupin in its business cycle?

Lupin Ltd's FY26 operating margin was 29.2%, against a 13-year range of 1.3% to 29.2%. The latest quarter was 26.1%, the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026).

What could break the Lupin story?

The main question: the P/E is near the low end of its own history, higher than only 4% of past readings, but results are getting worse. A low multiple can stay low until the quarters turn.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026).

Is Lupin a stock worth studying right now?

What the numbers show: Lupin Ltd's P/E is near the low end of its own history, higher than only 4% of past readings, and its quarterly results are still getting worse. The main open question: whether results start to improve.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026).

Is there a Lupin share price forecast for 2026?

What management itself guided: FY27 US revenues 1.1-1.2 billion dollars and operating margin 24-25% with H2 moderation flagged.

Where does this page get Lupin's management information?

From Lupin's results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results.

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 18 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.